Persistent Seronegativity and Absence of Intact Proviruses Despite Prolonged Initial Viremia in Early-Treated Perinatal HIV Infection - Scorecard - MDSpire
Advertisement
Persistent Seronegativity and Absence of Intact Proviruses Despite Prolonged Initial Viremia in Early-Treated Perinatal HIV Infection
Clinical Scorecard: Lack of Seroconversion and Intact Proviruses Despite Extended Initial Viremia in an Adolescent with Early-Treated Perinatal HIV Infection
At a Glance
Category
Detail
Condition
Perinatal HIV-1 infection with early antiretroviral treatment
Key Mechanisms
Persistent viremia despite early cART; absence of seroconversion and intact proviruses; defective proviruses detected; weak HIV-specific adaptive immune responses
Target Population
Adolescents with perinatal HIV infection treated early
Care Setting
Pediatric and adolescent HIV clinical care with virological and immunological monitoring
Key Highlights
Early cART initiation from 1 month of age with multiple regimen changes due to adherence issues.
Persistent viremia until 4 years of age despite treatment, followed by sustained viral suppression.
Absence of complete HIV seroconversion and no detectable intact proviruses at 11 and 18 years despite early infection.
Guideline-Based Recommendations
Diagnosis
Use of HIV-1 RNA quantification assays for early diagnosis in neonates.
Serial HIV serologies may be negative or weakly reactive despite infection in early-treated children.
Reservoir characterization including total HIV DNA and intact proviral DNA assays can inform persistence.
Management
Early initiation of combined antiretroviral therapy (cART) in perinatal HIV infection.
Address adherence challenges with sustained social and psychological support.
Adjust ART regimens as needed to achieve and maintain viral suppression.
Monitoring & Follow-up
Regular plasma HIV RNA viral load monitoring with ultrasensitive assays.
Periodic HIV serologic testing recognizing potential lack of seroconversion.
Immunologic assessments including CD4 counts, HIV-specific T-cell responses, and immune activation markers.
Risks
Poor adherence leading to prolonged viremia and potential viral reservoir persistence.
Potential misclassification of remission or cure due to absent seroconversion despite infection.
Limited HIV-specific adaptive immune responses may affect long-term viral control.
Patient & Prescribing Data
Adolescent with perinatal HIV infection treated from neonatal period
Multiple ART regimen modifications over childhood; sustained viral suppression achieved after adherence improvement; early treatment does not guarantee seroconversion or intact provirus presence.
Clinical Best Practices
Initiate cART as early as possible in perinatal HIV infection.
Implement multidisciplinary adherence support including social and psychological interventions.
Use ultrasensitive virological and immunological assays for comprehensive monitoring.
Recognize that absence of seroconversion does not exclude persistent infection or viral reservoirs.
Evaluate immune function broadly to understand host-virus interactions and guide management.
A small observational study in collegiate football players found microbiome associations after nonconcussive head impacts, though findings were limited by severe underpowering and high attrition
